decoglurant
Decoglurant is a negative allosteric modulator of the mGlu2 and mGlu3 receptors which was under development by Roche for the adjunctive treatment of major depressive disorder. Decoglurant progressed as far as phase II clinical trials but was ultimately discontinued from further development due to disappointing efficacy results. — Wikipedia
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started May 1, 2011 (NCT01367756)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 3MODULATOR
GRM3 modulator
Negative allosteric modulator (NAM). Removed from development pipeline January 2015 (http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm)
- Metabotropic glutamate receptor 2MODULATOR
GRM2 modulator
Negative allosteric modulator (NAM). Removed from development pipeline January 2015 (http://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm)
Chemistry & pharmacology
SMILES
Nc1ccc(C#Cc2cnn3c(C(F)(F)F)cc(-c4ccc(C(F)(F)F)cc4)nc23)cn1- Mol. weight
- 447.34 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDecoglurant ↗
- ChEMBLCHEMBL3301593 ↗
Also known as
- decoglurant
- decoglurant
- decoglurant
- rg-1578
- rg-1578
- ro4995819
- ro-4995819
- ro-4995819
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01901159 | Phase 1 | Jun 1, 2013 | Roche |
| NCT01733654 | Phase 2 | Sep 1, 2012 | Stanford University |
| NCT01457677 | Phase 2 | Dec 1, 2011 | Roche |
| NCT01409369 | Phase 1 | Aug 1, 2011 | Roche |
| NCT01457664 | Phase 1 | Jul 1, 2011 | Roche |
| NCT01367756 | Phase 1 | May 1, 2011 | Roche |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 5 | 5 | 2 | 2011 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2012 |